Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma

British Journal of Cancer

Volumn 70, Issue 4, 1994, Pages 636-641

  Seymour, L W ^a   Ulbrich, K ^b   Steyger, P S ^c   Brereton, M ^a   Subr, V ^b   Strohalm, J ^b   Duncan, R ^d  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^b INSTITUTE OF MACROMOLECULAR CHEMISTRY   (Czech Republic)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; FLUORESCEIN ISOTHIOCYANATE; POLYACRYLAMIDE; PRODRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG TARGETING; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIFESPAN; MALE; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMAL; CAPILLARY PERMEABILITY; DOXORUBICIN; FLUORESCEIN-5-ISOTHIOCYANATE; INJECTIONS, SUBCUTANEOUS; MACROMOLECULAR SYSTEMS; MALE; MELANOMA, EXPERIMENTAL; METHACRYLATES; MICE; MICE, INBRED STRAINS; MICROSCOPY, FLUORESCENCE; NEOPLASM TRANSPLANTATION; PRODRUGS; SUPPORT, NON-U.S. GOV'T; TISSUE DISTRIBUTION;

EID: 0028030559     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.1994.363     Document Type: Article

References (21)

1. BUTLER, T.P., GRANTHAM, F.H. & GULLINO, P.M. (1975). Bulk transfer of fluid in the interstitial compartment of mammary tumours. Cancer Res. 35, 3084–3090.
2. CASSIDY, J., DUNCAN, R., MORRISON, G.J., STROHALM, J., PLOCOVA, D., KOPECEK, J. & KAYE, S B. (1989). Activity of N-(2-hydroxypropyl)methacrylamide copolymers containing daunomvcin against a rat tumour model. Biochem. Pharmacol., 38, 875–879.
3. CHYTRY, V., KOPECEK, J., LEIBNITZ, E., O’HARE, K., SCARLETT, L. & DUNCAN, R. (1987). Copolymers of 6-o-methacryloyl-D-galactose and N-(2-hydroxypropyl)methacrylamide: Targeting to liver after intravenous administration to rats. New Polymeric Mat., 1, 21–28.
4. DUNCAN, R. (1992). Drug-polymer conjugates: potential for improved chemotherapy. Anticancer Drugs. 3, 175–211.
5. DUNCAN, R., KOPECEKOVA, P., STROHALM, J., HUME, I.C., LLOYD, J.B. & KOPECEK, J. (1988). Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. II, Evaluation of daunomycin conjugates in vivo against LI210 leukaemia. Br. J. Cancer. 57, 147–156.
6. DUNCAN, R., HUME, I.C., KOPECKOVA, P., ULBRICH, K., STROHALM, J. & KOPECEK, J. (1989). Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers, 3. Evaluation of adriamycin conjugates against mouse leukaemia LI210 in vivo. J. Controlled Release, 10, 51–63.
7. DUNCAN, R., SEYMOUR, L.W., O’HARE, K.B., FLANAGAN, P.A., WEDGE, S., HUME, I.C., ULBRICH, K., STROHALM, J., SUBR, V., SPREAFICO, F., GRANDI, M., RIPAMONTI, M., FARAO, M. & SUARATO, A. (1992). Preclinical evaluation of polymer-bound doxorubicin. J. Controlled Release. 19, 331–346.
8. FERRARA, N., HOUCK, K., JAKEMAN, L. & LEUNG, D.W. (1992). Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocrine Rev., 13, 18–32.
9. JAIN, R.K. (1990). Vascular and interstitial barriers to delivery of therapeutic agents in tumours. Cancer Metast. Rev., 9, 253–266.
10. JOHNSTON, G., BENNA, R.S. & TEATES, C.D. (1974). 67Gallium citrate imaging in untreated Hodgkin's disease: preliminary report of a co-operative group. J. Nucl. Med., 15, 399–404.
11. MAEDA, H. (1991). SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv. Drug Deliv. Rev., 6, 181–202.
12. MATSUMURA, Y. & MAEDA, H. (1986). A new concept for macromolecular therapeutics in cancer therapy: mechanism of tumoritropic accumulation of proteins and the antitumour agent SMANCS, Cancer Res., 46, 6387–6392.
13. NELSON, B., HAYES, R.L., EDWARDS, C.L., KNISELEY, R.M. & ANDREWS, G.A. (1972). Distribution of gallium in human tissues, after intravenous administration. J. Nucl. Med., 13, 92–100.
14. O’HARE, K.B., DUNCAN, R., STROHALM, J., ULBRICH, K. & KOPECKOVA, P. (1993). Polymeric drug carriers containing doxorubicin and melanocyte-stimulating hormone: In vitro and in vivo evaluation against murine melanoma. J. Drug Targeting. 1, 217–229.
15. RIHOVA, B., BILEJ, M., VETVICKA, V., ULBRICH, K., STROHALM, J., KOPECEK, J. & DUNCAN, R. (1989). Biocompatibility of N-(2-hydroxypropy!)methacrylamide copolymers containing adriamycin. Biomaterials. 10, 335–342.
16. SEYMOUR, L.W. (1992). Passive tumour-targeting of soluble macromolecules and drug conjugates. CRC.C., rit. Rev. Thera. Drug Carrier Sys., 9, 135–187.
17. SEYMOUR, L.W., ULBRICH, K., STROHALM, J., KOPECEK, J. & DUNCAN, R. (1990). Pharmacokinetics of polymer-bound adriamycin. Biochem. Pharmacol., 39, 1125–1131.
18. SEYMOUR, L.W., FLANAGAN, P.A., AL-SHAMKHANI, A., SUBR, V., ULBRICH, K., CASSIDY, J. & DUNCAN, R. (1991). Synthetic polymers conjugated to monoclonal antibodies: vehicles for tumour-targeted drug delivery. Selective Cancer Therapeut., 7, 59–73.
19. SEYMOUR, L.W., MIYAMOTO, Y., MAEDA, H., BRERETON, M., STROHALM, J., ULBRICH, K. & DUNCAN, R. (1994). Influence of molecular weight on passive tumour-accumulation of a soluble macromolecular drug carrier. Eur. J. Cancer (submitted).
20. SUZUKI, T., HONJO, I. & HAMAMOTO, K. (1971). Positive scinto-photography of cancer in the liver with 67Gallium citrate. Am. J. Roentgenol. Rad. Ther. Nucl. Med., 113, 92–99.
21. YEUNG, T.K., HOPEWELL, J.W., SIMMONDS, R., SEYMOUR, L.W., DUNCAN, R., BELLINI, O., GRANDI, M., SPREAFICO, F., STROHALM, J. & DUNCAN, R. (1991). Reduced cardiotoxicity of doxorubicin given in the form of N-(2-hydroxypropyl)methacryl-amide conjugates: an experimental study in the rat. Cancer Chemother. Pharmacol., 29, 105–111.